A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

ABSTRACT:

Background

The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown.

Trial design

2 × 2 factorial community randomized, double blind, trial.

Trial methods

32 communities with prevalence of trachoma ≥ 20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverag e> 90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the com

SUBMITTER: West SK 

PROVIDER: S-EPMC3757067 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature